Magnus Hansson, Chief Medical Officer and VP Preclinical & Clinical Development, ABLIVA |
 |
“We have retained a wide-ranging and successful collaboration with Isomerase for over 5 years. This has spanned both early stage drug discovery and support with later stage development, including discovery chemistry, candidate selection, assay development, process research and assistance with GMP manufacture. In addition to supporting the scientific base of the projects they have also been closely involved in business development and intellectual property generation & prosecution. They are truly a pleasure to work with and have very proactive and diligent mindsets. The Isomerase team has been key in the development of both our clinical and preclinical assets”
Magnus Hansson, Chief Medical Officer and VP Preclinical & Clinical Development, ABLIVA